LLY
Eli Lilly and Company
LLY has the edge over PETS overall, supported by stronger fundamentals and lower modeled downside.
PETS
PetMed Express, Inc.
PETS trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PETS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Strong |
PETS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PETS PE Valuation
PETS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PETS on the outlook, with more favorable earnings and revenue expectations.
PETS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect PETS's losses to grow, with revenue declining.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PETS on earnings quality, reporting a profit while its opponent remains loss making.
PETS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.27 | +$1.38 |
| Q2 2026 | -$1.37 | +$0.76 |
| Q1 2026 | -$2.74 | -$2.44 |
| Q4 2025 | -$3.12 | -15700% |
| Q3 2025 | -$2.65 | -$2.60 |
| Q2 2025 | -$2.13 | -$2.00 |
| Q1 2025 | -$0.30 | +$0.07 |
| Q4 2024 | $0.02 | +$0.17 |
PETS lost $1.27 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PETS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PETS on profitability, with a higher operating margin.
PETS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.8M | -19% |
| Q2 2026 | $41M | -20% |
| Q1 2026 | $42.8M | -16% |
| Q4 2025 | $40.7M | -23% |
| Q3 2025 | $44.4M | -26% |
| Q2 2025 | $51.2M | -25% |
| Q1 2025 | $50.8M | -24% |
| Q4 2024 | $53M | -19% |
PETS's revenue has slid since its 2020 peak: $36M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -18% | +0.9 points |
| Q2 2026 | -15% | +52 points |
| Q1 2026 | -13% | -1.4 points |
| Q4 2025 | -26% | -25 points |
| Q3 2025 | -19% | -20 points |
| Q2 2025 | -67% | -73 points |
| Q1 2025 | -12% | -6.1 points |
| Q4 2024 | -0.8% | +3.9 points |
PETS's operating margin was −18% last quarter, up 0.9 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PETS on cash generation, producing positive trailing cash flow while its opponent burns cash.
PETS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6M | +$3.2M |
| Q2 2026 | -$8.3M | +$5.2M |
| Q1 2026 | -$5.5M | -218% |
| Q4 2025 | -$9.2M | -$7.2M |
| Q3 2025 | -$4.8M | -178% |
| Q2 2025 | -$13.6M | -$4.4M |
| Q1 2025 | $4.6M | -21% |
| Q4 2024 | -$1.9M | +$1.8M |
PETS has burned cash in seven of the last eight quarters: −$25M over the past year, against −$16M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PETS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PETS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.8% | -610K shares |
| 1 year | +0.9% | +183K shares |
| 3 years | +1.4% | +292K shares |
| 5 years | +2.5% | +504K shares |
| Available history | +5.4% | +1.1M shares |
PETS has 21M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $1,000 |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PETS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -9.9x | Net Cash |
| Q4 2024 | -6.7x | Net Cash |
| Q3 2024 | -10.3x | Net Cash |
| Q2 2024 | -8.4x | Net Cash |
| Q4 2023 | -22.5x | Net Cash |
| Q3 2023 | -14.6x | Net Cash |
| Q2 2023 | -12.6x | Net Cash |
| Q1 2023 | -10.9x | Net Cash |
PETS has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PETS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.8 | Oversold |
| Stochastic | 5.8 | Oversold |
PETS's weekly RSI is 24 (oversold) and its Stochastic is 6 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PETS PE vs Healthcare Sector
| Metric | PETS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PETS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PETS on trend strength, trading above more of its moving averages.
PETS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.25 | 21% below |
| 20 week MA | $1.62 | 39% below |
| 50 week MA | $2.19 | 55% below |
| 100 week MA | $2.86 | 65% below |
| 200 week MA | $5.88 | 83% below |
PETS is in a downtrend: it's below all five of its weekly moving averages, and 83% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PETS on returns for 2026, with the stronger performance.
PETS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.1 | $33.8 | +46% |
| 2021 | $33.8 | $26.4 | -22% |
| 2022 | $26.4 | $18.1 | -31% |
| 2023 | $18.1 | $7.56 | -58% |
| 2024 | $7.56 | $5.16 | -32% |
| 2025 | $5.16 | $3.47 | -33% |
| 2026 YTD | $3.47 | $0.99 | -71% |
PETS has finished five years in a row lower, and it's down 71% so far in 2026.